Optimizing the use of irinotecan in colorectal cancer

Oncologist

Volumn 6, Issue SUPPL. 4, 2001, Pages 17-23

  Cunningham, David ^a   Maroun, Jean ^b,c   Vanhoefer, Udo ^d   Van Cutsem, Eric ^e  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 FU; Capecitabine; Colorectal cancer; Fluoropyrimidines; Irinotecan

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; HUMAN; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034791939     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_4-17     Document Type: Conference Paper

References (24)

1. Irinotecan in the treatment of colorectal cancer: Clinical overview
2. Topoisomerase I inhibitors: Topotecan and irinotecan
3. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
4. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
5. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy
6. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
7. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
8. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
9. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
10. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
11. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study
12. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
13. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
14. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
15. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
16. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
17. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC)
18. Survival as a function of response to first and second line treatment. A mathematical model for patients with metastatic colorectal cancer
19. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomised, phase III studies
20. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
21. Enhanced antitumor activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts
22. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
23. Capecitabine in combination with two schedules of irinotecan (CPT-11) in advanced colorectal cancer: A pilot experience
24. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer